Allogene Therapeutics, Inc. (ALLO) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
ALLO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ALLO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | 100.0% | -1241813.6% | -1170863.6% |
| 2023 | 100.0% | -344986.3% | -344489.5% |
| 2022 | -9063.5% | -215087.2% | -218214.1% |
| 2021 | 100.0% | -157.9% | -159.6% |
Download Data
Export ALLO earnings history in CSV or JSON format
Free sign-in required to download data
Allogene Therapeutics, Inc. (ALLO) Earnings Overview
As of May 8, 2026, Allogene Therapeutics, Inc. (ALLO) reported trailing twelve-month net income of -$191M, reflecting +34.1% year-over-year growth. The company earned $-0.87 per diluted share over the past four quarters.
Looking at the long-term picture, ALLO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2,000 in fiscal 2017.
Allogene Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CRSP (-$569M net income, -16569.8% margin), FATE (-$136M net income, -2051.1% margin), BEAM (-$65M net income, -57.2% margin), ALLO has comparable earnings metrics. Compare ALLO vs CRSP →
ALLO Earnings vs Peers
Earnings metrics vs comparable public companies
ALLO Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$191M | +25.9% | -$209M | $-0.87 | - | - |
| 2024 | -$258M | +21.3% | -$273M | $-1.32 | -1170863.6% | -1241813.6% |
| 2023 | -$327M | +3.9% | -$328M | $-2.09 | -344489.5% | -344986.3% |
| 2022 | -$340M | -87.0% | -$336M | $-2.38 | -218214.1% | -215087.2% |
| 2021 | -$182M | +27.2% | -$180M | $-1.34 | -159.6% | -157.9% |
| 2020 | -$250M | -35.6% | -$258M | $-2.08 | - | - |
| 2019 | -$185M | +12.7% | -$202M | $-1.83 | - | - |
| 2018 | -$212M | -10575150.0% | -$193M | $-2.36 | - | - |
| 2017 | $-2,000 | - | $-2,000 | $0.00 | - | - |
See ALLO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALLO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALLO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALLO — Frequently Asked Questions
Quick answers to the most common questions about buying ALLO stock.
Is ALLO growing earnings?
ALLO EPS is $-0.87, with earnings growth accelerating to +34.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-191M.
What are ALLO's profit margins?
Allogene Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ALLO's earnings?
ALLO earnings data spans 2017-2025. The accelerating earnings trend is +34.1% YoY. Historical data enables comparison across business cycles.